Login
Boehringer Ingelheim
  • Therapeutic Area
    • Metabolic
  • Resources
  • Contact
Login

 

Resources

Clinical studies

Carmelina Cardiovascular Results - No HHF

icoPDF

Carmelina Cardiovascular Results - No HHF
Carmelina Cardiovascular Results

icoPDF

Carmelina Cardiovascular Results
Carmelina Kidney Results - Lower Risk Of Albuminurea

icoPDF

Carmelina Kidney Results - Lower Risk Of Albuminurea
Carmelina Kidney Results

icoPDF

Carmelina Kidney Results
Safety

icoPDF

Safety
Trajenta Efficacy

icoPDF

Trajenta Efficacy vs
Trajenta Efficacy Regardless of Age

icoPDF

Trajenta Efficacy Regardless of Age
Trajenta Efficacy With Same Dose In Severe Renal Impairment

icoPDF

Trajenta Efficacy With Same Dose In Severe Renal Impairment
Trajenta Efficacy With Same Dose Regardless of Kidney Function

icoPDF

Trajenta Efficacy With Same Dose Regardless of Kidney Function
Trajenta Simplicity of Dosing

icoPDF

Trajenta Simplicity of Dosing
Trajenta Simplicity

icoPDF

Trajenta Simplicity
Trajenta Efficacy up to 104 Weeks vs Glimepride

icoPDF

Trajenta Efficacy up to 104 Weeks vs Glimepride
Trajenta Efficacy Added To Metformin

icoPDF

Trajenta Efficacy Added To Metformin
Trajenta Efficacy Regardless of BMI

icoPDF

Trajenta Efficacy Regardless of BMI
Trajenta Efficacy vs Pioglitazone

icoPDF

Trajenta Efficacy vs Pioglitazone
Carmelina Study Design

icoPDF

Carmelina Study Design
Carmelina Study Inclusion Criteria

icoPDF

Carmelina Study Inclusion Criteria
Carmelina Trial Overview

icoPDF

Carmelina Trial Overview
EMPA-REG OUTCOME Results

icoPDF

EMPA-REG OUTCOME Results
EMPA-REG Outcome Study Design

icoPDF

EMPA-REG Outcome Study Design
Load more
Close ×
  • Therapeutic Area
  • Metabolic
  • Resources
  • Videos
  • Clinical studies
  • Site map
  • Terms of use
  • Privacy
  • Contact
  • Change country

© 2010-2025
Boehringer Ingelheim International GmbH.
All rights reserved.